$ME->Wakeup('2021-02-15 00:00:00');
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The EUA was not denied, the FDA indicated they would like to see the results of the trial. The EUA is still pending and could be granted from trial results (This is what the FDA indicated). I am amazed at the amount of sellers/traders who didn't know this this but realize it is a result of their impatience and get rich quick mind set.
There are plenty of buyers/investors with dry powder who will be increasing their positions while weak hands get shook... You can watch the wealth transfer in real time, just need to keep the buy blocks small but frequent to keep adding without spiking it.
The drugs safety and efficacy are proven. The data speaks for itself and more data will be incoming soon.
Best,
JB
Agree completely. Nothing has changed other than we know for sure full trial results are needed. Weak hands being shook, I will be adding more today to transfer wealth from the impatient to the patient.
"If you aren't willing to own a stock for ten years, don't even think about owning it for ten minutes."
-Warren Buffett
Best,
JB
We are just waiting, news is coming and that news will be monumental. Will move RLFTF & their US Partner's pre merger SPAC shareprices significantly.
The results will speak for themselves and be undeniable. I look forward to a fresh set of diagnostic imaging (xrays). This runaway train is leaving the station, all aboard!
Best,
JB
CSLI CEO POSTS DECEMBER INVESTOR UPDATE ON FACEBOOK
http://imgur.com/a/dBUU3Mv
"Lifes a m*therf*c*ker"
-Samual Angel Barazza
-12/20/20
January will be the most exciting month yet for RLFTF
They are saving lives, we can only wait until the next PR is released. The case count and efficacy data will be exponentially increased. It's just a waiting game now but world changing news IS coming.
Best,
JB
Merry Christmas
BRPAR & BRPAW are both extremely undervalued. I believe people do not know what they are and they are unable to get on Robinhood either
I loaded up on BRPAR today 1/10 of a $50 stock for $1.40 seems pretty basic math to me :)
BRPAR is where the action is IMO
CSLI CEO POSTS DECEMBER INVESTOR UPDATE ON FACEBOOK
http://imgur.com/a/dBUU3Mv
"Lifes a m*therf*c*ker"
-Samual Angel Barazza
-12/20/20
I'm banking on the one that is a powerful vasodilator & bronchodilator. Seems to be not only safe and effective therapy for the deadly COVID-19 global pandemic. The one that based on its MOA might be beneficial to any respiratory ailment.
RLF is the golden goose 100 bagger
With regards to talking to the US, they said quote "not directly"... why, well they pay people to do for them and those people have.
I am a lifelong New Yorker and never have thought of the Swiss as being Lazy or Privileged. Its actually a wonderful country.
I also have owned ROCHE several times in my life but also know RLF is not locked into being a Swiss company, they could easily become a US company.
85/15 = Golden Goose , RLF has also indicated they want to acquire more talent and drugs/companies more than once. Maybe they buy NRX, who knows. All I know is my shares in both are on lockdown... Anyone selling either is foolish imo
RLF has the higher ceiling percentage wise imo, 100 bagger possibilty.
I didnt claim anything, I said it could.if anyone of several things occur. It would go back to the value of the trust
They are thinking "maybe" RLF will RM into this once its NRXP is up that RLF will then RM into... Again, 85/15 for the world. Whose the golden goose?
No idea what you are trying to say
I disagree with your valuation guesses. "If" Ketamine is approved for suicide, they might have something. It's just that though, Ketamine. Heck, I have even taken it at several "raves" in the 90s. Profit sharing in heavily in RLF favor. The world is much bigger than the US,Canada & Israel. Besides those, its 85/15...
Relief is the golden goose
This is still very speculative with far more risk than RLFTF imo. The RM could fall apart and then tank... NRX could violate and then void the profit sharing... Anything is possible but without RLF, they are just a bunch of nice resumes looking for work
Correct, $11.50 is the exercise/strike price
Spot on, NRX/BRPA gets less than half
Loaded for a while, holding onto shares and warrents
Look at this guys resume, world wide!
https://www.linkedin.com/in/chris-stijnen-68194110
21 December 2020
Geneva, Switzerland, December 21, 2020 – RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) ("Relief" or the "Company"), a biopharmaceutical company with its lead compound RLF-100TM (aviptadil) in advanced clinical development to treat severe COVID-19 patients, today announced the appointment of Christiaan ("Chris") L.J.J. Stijnen as Chief Commercial Officer (CCO) effective December 21, 2020. Mr. Stijnen will strengthen the management team in all activities pertaining to the commercialization of RLF-100™ and other future assets.
Mr. Stijnen is a highly experienced pharmaceutical executive with a successful track record in marketing, general management, access strategy and product development across a variety of indications. Prior to joining Relief, he had an impressive career with Bristol-Myers Squibb, where he was responsible for the marketing and commercialization of the company’s portfolio in various international subsidiaries between 2005 and March 2020. Most recently he was VP Product & Portfolio Strategy and Interim Head Commercial Strategy and Capabilities for Bristol-Myers Squibb China in Shanghai, China. Before that, he was Head Operations & Japan liaison, Product Portfolio and Access Strategy Department for Bristol-Myers Squibb Worldwide Commercial Organization in Princeton, New Jersey, USA. Prior to this, he developed early access strategies for specialty and orphan pipeline drugs as Access Strategy Lead Immunology, Fibrosis & Genetically Defined Diseases. Mr. Stijnen accumulated further product launch and commercialization experience as General Manager and President Director at Bristol-Myers Squibb locations in Russia, Turkey and Indonesia. His career with Bristol-Myers Squibb followed a 15-year tenure with Organon, which was acquired in 2007 by Schering-Plough Corporation (now part of Merck & Co.). At Organon, Mr. Stijnen helped launch various products and set up the Organon offices in Colombia to restructure commercialization activities in Central America. A native of The Netherlands, Mr. Stijnen earned a MSc. in Business Economics from Erasmus University Rotterdam.
https://relieftherapeutics.com/newsblog/relief-appoints-chris-l-j-j-stijnen-as-chief-commercial-officer
Someone like this doesn't come on board without big things in sight. It is a reality, the die has been cast. More news will be soon as well.
Best,
JB
I just hope that the share price doesn't drop like a rock! The dilution machine is cranked & ready to go........
I have my sights on RLFTF, anything else is just retribution. Based on the NRX SEC filing, we know what to expect to some degree.
Keep your seatbealt buckled, your arms and legs inside at all times, enjoy your time here at RLFTF
Best,
JB
Some thoughts on the SEC Filing:
https://www.sec.gov/Archives/edgar/data/1719406/000165495420013699/brpa_ex992.htm
The NRX SPAC merger document has provided our most recent up to date look at Relief’s data to date, specifically with the trial and future events. This SEC document was just filed yesterday. It notes that we now have: 200 enrolled in the clinical trial and 235
enrolled in the EAP trial.
This is a big gain from the 12/7/20 PR where they announced the 165 milestone in the clinical trial and 200 in the EAP.
More importantly, the SEC document mentions on page 4 “Validation from NIH, BARDA, and other stakeholders"
Lastly, on pg 18 of the report, “Inclusion in NIH TESICO/ACTIV3b trial” and an I-spy clinical trial contract for quantum healthcare.
ACTIV stands for Accelerating COVID-19 Therapeutic Interventions and Vaccines.
Heres the US NIH's ACTIV website:
https://www.nih.gov/research-training/medical-research-initiatives/activ#overview
Here is info about the I-Spy trial
https://www.quantumleaphealth.org/portfolio/i-spy-covid
BARDA as a possible stake holder on page 4 is a big deal. The RLF EGM PR specifically said "not directly" for a reason. I feel like we’re finally getting more proof of all the great things RLF & NeuroRx have been doing these past few months while we held. I suspect when we finally get EUA, there’s going to be a flood of news regarding Data,OWS, BARDA, manufacturing with Bachum, Nephron -and delivery with our unknown delivery contractor
Bottom line is that "ITS A BIG FKN DEAL"...
Best,
-JB
This was a big part of my basis of an imminent data read out coming. The numbers are exponentially increasing. It is probably the best glimpse into the trial and our US partner NRX we have seen to date. If you can't beat 'em, join them eh?
Regardless, thank the current you for posting. Stay safe.
All the best,
JB
Because the trial is for 165 patients, makes sense to do a read of 165 EAP patients as well for comparative purposes. I'd also assume we will see comparative results of 90 EAP vs either 90 non placebo or 90 placebo. Maybe your right, maybe we will see data on 137,161,168 ... We will see more data soon though
I do disagree that a data release would be viewed as a "pump before poor trial results". Showing great results in patients too sick for your trial is only good news. Imagine what the trial results will be like!!!
Best,
JB
We know that on 11/23, "more than 175" EAP patients had been enrolled. So it is a safe assumption that 165 of them are at LEAST 25+ days out. Expect a data read out of those 165 VERY soon....
Best,
JB
https://relieftherapeutics.com/newsblog/neurorx-and-relief-announce-initial-successful-results-from-expanded-access-use-of-rlf-100-aviptadil-in-patients-with-critical-covid-19-and-severe-comorbidity-72-survival-seen-in-icu-patients
28 days for 165 EAP patients, not trial (yet)
Get ready for more people realizing they should cash out while they can. There is no data to hold this price. It's going down down down
Very interesting that Chords has a drug in the pipeline for an disease that targets the optic nerves. Someone has EYES on this.
We should be at 165 EAP patients 28 days out... There will be a PR, we already know that both efficacy and safety will be shown in it.
Why is RVVTF tanking? No news from trials?? No news OF a trial??
Yes, they asked for more shares to be authorized in case they needed to acquire talent and another company. It was approved as well. Thats good news, even better would be if they issued these shares to do so
This is from the "horses mouth" as well
Down 5% already.... "How low can you go"
SELL MORTIMER, SELL!
LOOK OUT BELOW!
No trial results, no data, no patient success stories. Nothing. Just share price dropping
Dr. Jonathan Javitt did not accept his nomination, as announced at the 2020 Ordinary General Meeting, to join the Relief Board of Directors.
Further, Relief has not directly had any discussions with Operation Warp Speed or any other U.S. government agency.
https://relieftherapeutics.com/newsblog/relief-announces-results-of-extraordinary-general-meeting-of-relief-therapeutics-holding-ag-approved-with-large-majority
Based on this we can assume that:
1) Some entity has had contact with OWS, most likely NRX.
2) RLF has had direct contact with some non US government agency
Ruh Roh... what is going on with share price? What is going on with trial? ¯\_(?)_/¯
No trial no data... prove me wrong...
RVVTF is "groovy" vaporware